Brain PET Tracers Compared: FDG, Amyloid, DAT, FET, Tau

Brain PET imaging has fragmented into multiple specialized tracers, each answering a specific clinical question. FDG remains the workhorse for general metabolism, but increasingly clinical decisions hinge on tracers that target proteins (amyloid plaques, tau tangles), receptors (dopamine transporters), or amino acid uptake (FET for tumor activity). Choosing the right tracer is often more important than choosing a top center. This guide compares the major brain PET tracers, their clinical scenarios, and global availability in 2026.

Why Brain PET Needs Multiple Tracers

The brain consumes about 20% of the body's glucose despite being only 2% of body mass. Background cortical FDG uptake is so high that detecting subtle abnormalities — small tumor recurrences, early dementia patterns, focal seizure foci — can be challenging. Specialized tracers target lower-background biological processes for higher diagnostic contrast.

Each tracer answers a different question:

• "Is brain metabolism reduced in a recognizable pattern?" → FDG
• "Are amyloid plaques present?" → amyloid tracers
• "Are tau tangles present?" → tau tracers
• "Is there active tumor vs radiation necrosis?" → FET or methionine
• "Is dopaminergic function intact?" → DAT (SPECT or PET)

FDG: General Metabolism (Most Common)

F-18 FDG remains the most widely available brain PET tracer. Clinical applications:

• Dementia differential diagnosis (Alzheimer's, frontotemporal, Lewy body, vascular)
• Brain tumor recurrence (limited compared to FET)
• Focal epilepsy seizure focus localization (interictal hypometabolism)
• Atypical parkinsonism (vs Parkinson's, MSA, PSP)

Strengths: widely available at almost every PET center; well-validated for many indications; cost is the lowest of all brain PET tracers.

Limitations: high background cortical uptake limits sensitivity for small lesions; cannot distinguish amyloid plaques from other Alzheimer's pathology; cannot detect specific protein deposits.

Cost: $3,000–5,000 US, ¥5,000–8,000 mainland China.

Amyloid PET: Alzheimer's Workup

Amyloid PET tracers target the beta-amyloid plaques that are a defining pathological feature of Alzheimer's disease. Three main tracers:

• Florbetapir (F-18, Amyvid) — first FDA approved
• Florbetaben (F-18, Neuraceq) — European-developed; widely available
• Flutemetamol (F-18, Vizamyl) — third option

Clinical applications:

• Confirming or excluding Alzheimer's-type pathology in patients with cognitive decline
• Pre-treatment evaluation before anti-amyloid drugs (aducanumab, lecanemab, donanemab)
• Excluding Alzheimer's pathology in atypical dementia presentations

Strengths: highly specific for amyloid plaques; effectively rules out Alzheimer's when negative.

Limitations: positive amyloid PET can occur in cognitively normal elderly (15–30% by age 75); does not directly correlate with severity of dementia.

Cost: $5,000–7,500 US (Medicare coverage expanded 2023), $3,000–4,500 UK private, ¥8,000–12,000 mainland China.

Tau PET: Newer Alzheimer's Marker

Tau PET tracers detect tau protein neurofibrillary tangles, the second hallmark of Alzheimer's pathology:

• Flortaucipir (F-18, Tauvid) — FDA approved 2020
• MK-6240, PI-2620 — newer-generation tracers

Tau PET correlates better with cognitive decline than amyloid PET. Amyloid plaques can be present without clinical disease; widespread tau tangles essentially are the disease.

Clinical applications:

• Confirming active Alzheimer's pathology (vs amyloid alone)
• Monitoring disease progression
• Discrimination of Alzheimer's from primary tauopathies (PSP, CBD)
• Research and clinical trial enrollment

Availability is more limited than amyloid PET. Cost: $4,500–6,500 US, ¥9,000–14,000 mainland China at specialized centers.

DAT (DaTscan): Parkinsonian Syndromes

DAT (dopamine transporter) imaging is technically SPECT in most clinical practice, using I-123 ioflupane (DaTscan). PET DAT tracers (F-18 FE-PE2I) exist but are less common.

Clinical applications:

• Distinguishing Parkinson's disease (and atypical parkinsonisms — MSA, PSP, DLB) from essential tremor and drug-induced parkinsonism
• All true Parkinsonian syndromes show reduced striatal DAT binding; essential tremor and drug-induced parkinsonism do not

Strengths: clear binary result for the differential diagnosis; widely available; relatively low cost.

Limitations: does not distinguish among Parkinson's vs MSA vs PSP (all show reduced DAT); FDG patterns then differentiate these.

Cost: $2,500–4,000 US, ¥3,000–5,000 mainland China.

For complex movement disorder workup with DAT and FDG, our team can help.

FET and MET: Brain Tumor Recurrence

For evaluating brain tumor recurrence after surgery and radiation, amino acid tracers outperform FDG:

• F-18 FET (Fluoroethyltyrosine) — most widely used in Europe
• C-11 methionine (MET) — research and select centers
• F-18 DOPA — alternative amino acid tracer

These tracers are taken up by amino acid transporters that are upregulated in tumor cells but minimal in normal brain. Tumor recurrence shows FET-avid lesions; radiation necrosis is FET-cold.

Strengths: sensitivity 85–95% for distinguishing tumor recurrence from radiation necrosis (FDG ~60–80%).

Limitations: not widely available in the US (cyclotron production needed); requires expert interpretation; few US Medicare-approved indications.

Availability: well-established in Europe (Germany, France, Italy) and increasingly in China. Top Chinese neuro-oncology centers (Huashan Shanghai, Tiantan Beijing, PUMC) carry FET.

Cost: $4,500–6,000 US (research access mostly), £2,500–3,500 UK private, ¥8,000–12,000 mainland China.

Availability and Cost by Tracer

Tracer	US (cash)	UK private	Mainland China	Availability
FDG	$3,000–5,000	£1,500–2,500	¥5,000–8,000	Universal
Amyloid (florbetaben/florbetapir/flutemetamol)	$5,000–7,500	£3,000–4,500	¥8,000–12,000	Major academic centers
Tau (flortaucipir)	$4,500–6,500	£3,000–4,500	¥9,000–14,000	Limited to specialized centers
DAT (DaTscan)	$2,500–4,000	£1,200–1,800	¥3,000–5,000	Most academic centers
FET	$4,500–6,000	£2,500–3,500	¥8,000–12,000	Europe + select Chinese neuro centers
MET (methionine)	Research only	Research only	Limited Chinese centers	Very limited
F-18 DOPA	$4,000–5,500	£2,500–3,500	¥7,000–10,000	Select centers

US Medicare and major commercial insurers now cover amyloid PET for clinical Alzheimer's workup (expanded 2023). DAT SPECT is covered for clinical parkinsonism workup. Tau PET coverage is more limited.

Pathway for International Brain PET in China

Top Chinese centers with comprehensive brain PET menu:

• Huashan Hospital, Shanghai (Fudan University) — dementia and movement disorder reference center; carries all major tracers including amyloid, tau, DAT, FET
• Tiantan Hospital, Beijing — leading neurosurgical center; FET PET routine for brain tumor follow-up
• Xuanwu Hospital, Beijing — dementia and Parkinson's specialty
• Peking Union Medical College Hospital, Beijing — research and clinical PET access
• West China Hospital, Chengdu — comprehensive brain PET program

International patient pathway:

1. Send prior MRI, EEG, neuropsychological testing, prior PET if any
2. Pre-arrival video consultation with neurology or neuro-oncology
3. Arrival: in-person specialist consultation
4. PET scan day (half-day)
5. Results review and treatment plan
6. Departure or continued treatment

Total stay: 4–7 days. The specialty consultation is often more time-consuming than the scan itself.

Frequently Asked Questions

Which brain PET tracer should I get?
Depends on the clinical question. Dementia workup: FDG first, amyloid PET if Alzheimer's specifically suspected, tau PET to confirm. Brain tumor follow-up: FET if available, FDG if not. Parkinsonism: DAT first, FDG for atypical parkinsonism subtyping.

Why isn't tau PET more widely available?
Tau tracers are newer (flortaucipir FDA-approved 2020) and require cyclotron production with shorter shelf-life logistics. Coverage and reimbursement also lag amyloid PET.

Can amyloid PET diagnose Alzheimer's by itself?
No. Amyloid plaques are present in 15–30% of cognitively normal elderly. A positive scan plus clinical symptoms supports the diagnosis. A negative scan effectively rules out Alzheimer's.

Is FET PET FDA approved in the US?
Not yet (as of early 2026). Some academic centers run FET research protocols. For most US patients needing distinction of tumor recurrence from radiation necrosis, FDG remains the routine tracer.

Can I get amyloid PET if I'm not symptomatic?
Yes for self-pay and research. Insurance typically requires clinical Alzheimer's workup with positive cognitive testing. For asymptomatic high-risk patients (familial Alzheimer's), self-pay amyloid PET is increasingly common.

Does the scan take the same time as FDG PET?
Yes, roughly. The uptake phase varies (FDG 60 min, amyloid/tau 90 min, FET 30-40 min). Total clinic time is 90-150 minutes.

Need Help Booking?

SinoCareLink can pre-book brain PET (FDG, amyloid, tau, FET, DAT) at a top Chinese neurological center, coordinate neurology and neuro-oncology consults, translate reports into English, and arrange airport pickup. Contact us for a free consultation.